Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development. Lepak A, Bhavnani SM, Castanheira M, Rubino CM, et al. Antimicrob Agents Chemother 2026 Jan 30:e0164325. doi: 10.1128/aac.01643.

Read + Share

Amedeo Smart

Independent Medical Education

Lepak A, Bhavnani SM, Castanheira M, Rubino CM, et al. Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development. Antimicrob Agents Chemother 2026 Jan 30:e0164325. doi: 10.1128/aac.01643.
PMID: 41616263